CTOs on the Move

National Foot Care Program

www.nationalfootcare.com

 
National Foot Care Program is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

S.A.F.T.E. (Safety Alert for the Elderly)

S.A.F.T.E. (Safety Alert for the Elderly) is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Erba Diagnostics

ERBA Diagnostics Inc., is a part of the global ERBA Mannheim Group. Earlier known by the name of IVAX Diagnostics, the company specializes in manufacture and marketing of proprietary diagnostic reagents, test kits and instrumentation in the areas of autoimmune, chemistry, hematology, diabetes and infectious diseases. ERBA Diagnostics has further strengthened ERBA Group`s comprehensive portfolio of instrument and reagent solutions, covering all levels of automation and throughput needs of laboratories across the world. With its team of experienced marketing, technical and service professionals and a strong and extensive distribution network the company lives up to the ERBA Group`s philosophy of consistently delivering excellence through innovation, technology and customer service.

New England Institutional Review Board NEIRB

New England Institutional Review Board NEIRB is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.